U.S. Markets closed

CareDx Presents the Latest AlloSure Data in Virtual Meetings

Leading transplant clinicians to present ten abstracts accepted for presentation at the American Transplant Congress

SOUTH SAN FRANCISCO, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- CareDx, Inc. (CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today the delivery of content on state-of-the-art research accepted at the American Transplant Congress (ATC) annual meeting scheduled for May 30-June 1, 2020.

CareDx’s program will include two virtual abstract sessions with prominent authors delivering ten abstracts accepted for presentation at the ATC Annual Scientific Sessions. A virtual symposium will also be held with leaders in the field of transplantation delivering cutting edge content on AlloSure, AlloMap, iBox, and KidneyCare. Additionally, CareDx will host a Transplant Celebration event with performances from the transplant community and a telemedicine panel with the CEO of Doxy.me. Registration information for CareDx virtual programming can be found at caredx.com/atc.

On Thursday, May 28, 2020, 3:00 PM EDT, five abstracts will be presented:

  • Role of Cell Free DNA (AlloSure) Testing in Recipients of Kidneys with Sub Optimal Donor Quality – Yasir Qazi, MD, Keck, University of Southern California

  • Characterization of An Integrative Prognostic Score For U.S. Patients Taken From the Dart Study – Abdolreza Haririan, MD, University of Maryland

  • Donor-derived Cell-free DNA For Detection Of Cell-mediated Rejection In Low Risk Kidney Transplant Patients – Sanjiv Anand, Intermountain Medical Center

  • Center Experience with dd-cfDNA in Lung Transplantation – Deborah Jo Levine, MD, UT Health San Antonio

  • Impact of Kidney Transplant Type and Previous Transplant on Baseline Donor-derived Cell-free DNA – Kalathil Sureshkumar, MD, Allegheny

On Friday, May 29, 2020, 3:00 PM EDT, a virtual symposium on COVID-19 in Transplant, Telemedicine, and AlloSure clinical data and case examples will be presented, chaired by Manikkam Suthanthiran, MD, Weill Cornell Medicine and featuring the following speakers:

  • Hannah A. Valantine, MD, NIH

  • Marlon Levy, MD, Virginia Commonwealth University

  • Nicolae Leca, MD, University of Washington

  • Robert Stratta, MD, Wake Forest

  • Stanley Jordan, MD, Cedars Sinai

  • George Burke, MD, Jackson Memorial

On Friday, May 29, 2020 5:00 PM EDT CareDx will be hosting a press conference on the latest innovations in transplantation with the following speakers:

  • Peter Maag PhD, CEO and Chairman at CareDx

  • David Guthrie, Chief Product Officer Patient Point and lung transplant recipient

  • Medhat Askar, MD, PhD, Baylor University Medical Center

  • Alexandre Loupy, MD, PhD, Paris Transplant Group

On Tuesday, June 2, 2020, 3:00 PM EDT, five abstracts will be presented:

  • The Use of AlloSure Donor Derived Cell-free DNA in a Community Based Kidney Transplant Program – Velma P. Scantlebury, MD, ChristianaCare

  • Peds Post Rejection Treatment, Biopsy Proven (Both T Cell And B Cell) Looking at AlloSure 3 Months Post, Along with AT1R and DSA – Dechu Puliyanda, MD, Cedars Sinai

  • Value of dd-cfDNA When Considering Recipient Ethnicity to Further Help Risk Stratify Transplant Recipients – Anthony Langone, MD, Vanderbilt

  • Utility of dd-cfDNA in TCMR 1A and Borderline Allograft Rejection – Erik Stites, MD, UCHealth

  • Characterization of an Integrative Prognostic Score for US Patients Taken from the Dart Study – Daniel Brennan, MD, Johns Hopkins

“We look forward to contributing to the virtual ATC meeting and continuing to drive innovation in transplant by sharing these latest abstracts virtually. This is a critical time for the transplant community to come together, and we are creating a space for shared experiences and learning,” says Peter Maag, CEO of CareDx.

About CareDx
CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

CONTACTS:

CareDx, Inc.
Sasha King
Chief Marketing Officer
415-287-2393
sking@caredx.com

Investor Relations
Greg Chodaczek
646-924-1769
investor@caredx.com

Latest Stories

  • 3 tax breaks included Biden's economic 'rescue plan'

    President-elect Joe Biden’s $1.9 trillion “rescue plan” released on Thursday calls for three key tax improvements for 2021 that would help Americans across the income spectrum.

  • Joe Biden's $1.9 trillion stimulus plan could wreck Wall Street's favorite money-making trade

    Tech stocks could come under pressure as President-elect Joe Biden's stimulus plan works its way through the U.S. economy.

  • Dow Slides As Biden Stimulus Plan Raises These Fears; GM Reverses As IPO Stock Passes Buy

    The Dow Jones slid lower amid fears Joe Biden's massive stimulus plan could lead to higher interest rates or tax hikes. GM stock reversed.

  • Raymond James: 2 Big 7% Dividend Stocks to Buy Now

    Watching the markets with an eye to the main chance, Raymond James strategist Tavis McCourt sees both risk and opportunity in current market conditions. The opportunity, in his opinion, stems from the obvious factors: the Democrats won both Georgia Senate seats in the recent runoff vote, giving the incoming Biden Administration majority support in both Houses of Congress – and increasing the odds of meaningful fiscal support getting signed into law in the near term. More importantly, the coronavirus vaccination program is proceeding, and reports are showing that Pfizer’s vaccine, one of two approved in the US, is effective against the new strain of the virus. A successful vaccination program will speed up the economic recovery, allowing states to loosen lockdown regulations – and get people back to work. The risks are also coming from the political and public health realms. The House Democrats have passed articles of impeachment against President Trump, despite the imminent natural closure of his term of office, and that passage reduces the chances of political reconciliation in a heavily polarized environment. And while the COVID strain is matched by current vaccines, there is still a risk that a new strain will develop that is not covered by existing vaccinations – which could restart the cycle of lockdowns and economic decline. Another risk McCourt sees, beyond those two, would be a sharp rise in inflation. He doesn’t discount that, but sees it as unlikely to happen soon. “…product/service inflation is only really a possibility AFTER re-openings, so the market feels a bit bullet proof in the very near term, and thus the continued rally, with Dems winning the GA races just adding fuel to the stimulus fire,” McCourt noted. Some of McCourt’s colleagues among the Raymond James analyst cadre are keeping these risks in mind, and putting their imprimatur on strong dividend stocks. We’ve looked into Raymond James' recent calls, and using the TipRanks database, we’ve chosen two stocks with high-yield dividends. These Buy-rated tickers bring a dividend yield of 7%, a strong attraction for investors interested in using the current good times to set up a defensive firewall should the risks materialize. Enterprise Products Partners (EPD) We’ll start in the energy sector, a business segment long known for both high cash flows and high dividends. Enterprise Products Partners is a midstream company, part of the network that moves hydrocarbon products from the wellheads to the storage farms, refineries, and distribution points. Enterprise controls over 50,000 miles worth of pipelines, shipping terminals on Texas’ Gulf coast, and storage facilities for 160 million barrels oil and 14 billion cubic feet of natural gas. The company was hurt by low prices and low demand in 1H20, but partially recovered in the second half. Revenues turned around, growing 27% sequentially to reach $6.9 billion in Q3. That number was down year-over-year, slipping 5.4%, but came in more than 6% above the Q3 forecast. Q3 earnings, at 48 cents per share, were just under the forecast, but were up 4% year-over-year and 2% sequentially. EPD has recently declared its 4Q20 dividend distribution, at 45 cents per common share. This is up from the previous payment of 44 cents, and marks the first increase in two years. At $1.80 annualized, the payment yields 7.9%. Among the bulls is Raymond James' Justin Jenkins, who rates EPD a Strong Buy. The analyst gives the stock a $26 price target, which implies a 15% upside from current levels. (To watch Jenkins’ track record, click here) Backing his bullish stance, Jenkins noted, "In our view, EPD's unique combination of integration, balance sheet strength, and ROIC track record remains best in class. We see EPD as arguably best positioned to withstand the volatile landscape… With EPD's footprint, demand gains, project growth, and contracted ramps should more than offset supply headwinds and lower y/y marketing results…" It’s not often that the analysts all agree on a stock, so when it does happen, take note. EPD’s Strong Buy consensus rating is based on a unanimous 9 Buys. The stock’s $24.63 average price target suggests an upside of 9% from the current share price of $22.65. (See EPD stock analysis on TipRanks) AT&T, Inc. (T) AT&T is one of the market’s instantly recognizable stock. The company is a member in long standing of the S&P 500, and it has reputation as one of the stock market’s best dividend payers. AT&T is a true large-cap industry giant, with a market cap of $208 billion and the largest network of mobile and landline phone services in the US. Its acquisition of TimeWarner (now WarnerMedia), in a process running between 2016 and 2018, has given the company a large stake in the mobile content streaming business. AT&T saw revenues and earnings decline in 2020, under pressure from the corona pandemic – but the decline was modest, as that same pandemic also put a premium on telecom and networking systems, which tended to support AT&T’s business. Revenues in 3Q20 were $42.3 billion, 5% below the year-ago quarter. On positive notes, free cash flow rose yoy from $11.4 billion to $12.1 billion, and the company reported a net gain of 5.5 million new subscribers. The subscriber growth was driven by the new 5G network rollout – and by premium content services. The company held up its reputation as a dividend champ, and has made its most recent dividend declaration for payment in February 2021. The payment, at 52 per common share, is the fifth in a row at current level and annualizes to $2.08, giving a yield of 7.2%. For comparison, the average dividend among tech sector peer companies is only 0.9%. AT&T has kept its dividend strong for the past 12 years. Raymond James analyst Frank Louthan sees AT&T as a classic defensive value stock, and describes T’s current state as one with the bad news ‘baked in.’ “[We] believe there is more that can go right during the next 12 months than can get worse for AT&T. Throw in the fact that shares are heavily shorted, and we believe this is a recipe for upside. Large cap value names are hard to come by, and we think investors who can wait a few months for a mean reversion while locking in a 7% yield should be rewarded for buying AT&T at current levels,” Louthan opined. In line with these comments, Louthan rates T an Outperform (i.e. Buy), and his $32 price target implies room for 10% growth from current levels. (To watch Louthan’s track record, click here) What does the rest of the Street think? Looking at the consensus breakdown, opinions from other analysts are more spread out. 7 Buy ratings, 6 Holds and 2 Sells add up to a Moderate Buy consensus. In addition, the $31.54 average price target indicates ~9% upside potential. (See AT&T stock analysis on TipRanks) To find good ideas for dividend stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Rally Quickly Turns 7 Penny Stocks Into Billion-Dollar Companies

    Some left-for-dead penny stocks are now billion-dollar companies, thanks to the rally in the S&P 500 and other indexes.

  • I took care of my late mother for 8 years. Am I obliged to tell my sisters she made me co-owner of a substantial bank account?

    This daughter writes: ‘My conscience is getting the better of me, and I would like to be transparent about being the joint owner of this savings account.’

  • How do I reduce the taxes on my estate?

    Q.: To lessen the death tax on my estate, if I put my Roth IRA in an irrevocable trust now and after my spouse and I die four years later, do my children afterward have six years or 10 years to invest all the money before they must dispose of the Roth money from the trust under the new rules of the 2019 SECURE Act? A.: John, you cannot put a Roth IRA in a trust while you are alive. You can move the assets in the Roth IRA out of the Roth IRA and then put those assets into the trust but trusts can only own Roth IRAs as Inherited Roth IRAs.

  • Value stocks are about to come out of their coma, says index fund powerhouse Vanguard

    The idea that value stocks are finally about to awaken after a decadelong slumber is almost a joke in financial circles. What is at least slightly different about Vanguard’s perspective is that its model suggests that investors have been correct in shunning value stocks, at least until the last few years. “Our research indicates that a value premium does exist and that the recent outperformance of growth stocks can be partially explained by downward-trending long-term inflation levels and the lack of material acceleration in earnings growth over the last decade,” the firm says.

  • Sorrento Stock Could Hit $30, Says Analyst

    The major U.S. equity-indexes are hovering around all-time highs, and a question that frequently pops up these days, is whether some companies’ valuations might be overstretched. However, some operate at the opposite end of the spectrum, and could yet offer investors untapped opportunities. H.C. Wainwright analyst Ram Selvaraju points in the direction of Sorrento Therapeutics (SRNE), as one such company. Selvaraju rates SRNE a Buy along with a $30 price target, which implies a 275% upside from current levels. (To watch Selvaraju’s track record, click here) So, what’s behind the optimistic outlook? Well, for starters, Sorrento has a stake in two cell-based immunotherapy companies that could “drive value in Sorrento shares over the coming months.” One is Celularity, a clinical-stage cell therapeutics company focused on cellular medicines for cancer, infectious diseases, and degenerative diseases. Celularity is expected to go public later this year via a SPAC merger with GX Acquisition Corp. The merged company’s equity value following the transaction’s closure will land at roughly $1.7 billion. Selvaraju estimates Sorrento's position should be worth in the $200 million region. The second company is NantKwest, which recently signed a deal to merge with ImmunityBio. The transaction is expected to close in 1H21. Sorrento owns roughly 8.2 million shares of the clinical-stage immunotherapy company. These are currently worth around $121 million, going by NantKwest’s recent share price. Additionally, the analyst highlights Sorrento’s “burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology and COVID-19).” In fact, on the Covid-19 front alone, Sorrento has taken a broad-based approach and has a long list of diagnostic, prophylactic and therapeutic offerings in the pipeline, with “updates likely to come fast and furious.” These include two rapid detection tests; COVI-STIX, for which the company filed for Emergency Use Authorization (EUA) in the U.S. in December, and COVI-TRACE, which Selvaraju claims could come in handy at any mass gathering event. “We believe that the incentive to facilitate the large-scale and indeed ubiquitous deployment of the COVI-TRACE test is extremely high and governments worldwide may seek to implement this in their respective regions,” the 5-star analyst opined. Other Covid-19 candidates include COVIGUARD - a SARS-CoV-2 neutralizing antibody, COVI-AMG - an affinity-matured version of the COVIGUARD neutralizing antibody, a neutralizing antibody cocktail named COVI-SHIELD and COVIDTRAP, an ACE2 receptor decoy, intended to imitate the mammalian ACE2 receptor that acts as the primary portal for the SARS-CoV-2 virus to penetrate human cells. It has been relatively quiet when it comes to other analyst activity. In the last three months, only 2 analysts have issued ratings. However, as they were both Buys, the word on the Street is that SRNE is a Moderate Buy. Based on the $25.50 average price target, shares could climb 219% higher in the next twelve months. (See SRNE stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Bank of America's 8 Best Stocks to Buy in Q1

    Here are analysts' top stocks to buy in the first quarter.The S&P 500 closed out 2020 at all-time highs on optimism surrounding additional government stimulus measures and a potential global economic rebound in 2021.

  • Four things that could pop the 'rational bubble' in equities: Mohamed El-Erian

    Four things could pop the "rational bubble" in equities, says Mohamed El-Erian — even if they're not likely to happen right now.

  • Buy Zoom Video Stock, Analyst Says. It’s Just Too Cheap Right Now.

    Zoom stock has tumbled about 35% since mid-October, as investors have questioned how much the company’s growth rate will compress once the economy reopens.

  • I don’t know if my 3-year-old daughter will go to college, so would saving through my retirement account be more flexible than starting a 529 plan?

    After her birth I wanted to establish a 529 plan. Now that we’re heading into 2021 with all this talk about debilitating college loan debt, I’ve started wondering if it still makes sense to start a brand-new 529 plan or just simply keep contributing to my current 403(b) retirement account, then tapping that early for her, if needed.

  • U.S. Stock Futures Decline After Biden’s Spending-Bill Proposal

    (Bloomberg) -- U.S. stock futures fell, erasing early gains, as investors assessed the details of President-elect Joe Biden’s $1.9 trillion spending-bill proposal that includes $350 billion in aid to states.Contracts on the S&P 500 Index were down 0.4% as of 11:36 a.m. in London, after rising as much as 0.2% earlier. The underlying index lost 0.4% in the cash session, with investors growing concerned about the path for Federal Reserve policy now that signs of faster inflation are emerging.In Europe, the Stoxx Europe 600 Index followed through, dropping as much as 0.7%, dragged lower by energy and mining shares. The health care sector outperformed and was the only industry group firmly in the green.The Fed’s largesse and prior federal spending packages worth almost $3 trillion have powered a 70% gain in U.S. stocks from the pandemic lows in March. Biden’s plan -- long telegraphed since his election in November -- is more than double the package approved in late December, and proposes sending $1,400 to qualified individuals. It also calls for increasing the federal minimum wage to $15 an hour.U.S. stocks have pushed to record after record since the vaccine approvals and Biden’s election in November. His agenda, including ambitious aid and a follow-up plan to spend on projects such as infrastructure, got a boost Jan. 5 when Democrats won control of the Senate.Vice President Kamala Harris’ vote should help seal Democratic wins on issues that require a simple majority for passage in the evenly split upper house. However, Biden proposals including aid to states and money for health care are likely to require 60 votes, which would appear difficult to achieve.“Given the distaste Republicans have for state aid, Mr. Biden’s bipartisan hopes will be immediately tested,” Jeffrey Halley, senior market analyst with Oanda Asia Pacific Pte., wrote in a note. “And that is before the remake America bills come through with the almost certain increases in taxes.”The record climbs in stocks have stretched valuations to levels not seen in two decades, prompting warnings of a bubble that will lead to a rapid selloff. Investors have tolerated them so far because of Biden’s pledge to amp up spending not only on direct aid, but also on fighting the virus and rolling vaccines. His bill sets aside $20 billion for a national vaccine program and $50 billion to expand testing capacity.Signs of froth abound, though. In a note titled “This Is Ludicrous,” Bespoke Investment Group summed up the recent action. It cited 59 U.S.-listed stocks that are trading at prices that are more than 10 times sales and have more than doubled in the past three months. Stocks currently in that category have risen 760% since March and have a combined market capitalization of $320 billion, according to George Pearkes, global macro strategist at the firm.“Stimulus is always going to be net positive for near-term growth and profits, but the question is always how much is already priced in,” said Dan Suzuki, deputy chief investment officer at Richard Bernstein Advisors. “There’s more room for stimulus to get priced in from here, but it only adds to the cyclical recovery that will likely take place regardless of whether stimulus gets passed.”(An earlier version of this story was corrected to reflect the size of the plan in the first paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Fastest-Growing Stocks: Square Stock Among 7 Stocks Expecting Up To 156% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring GRWG stock, Square, Daqo and four other stocks expecting up to 156% growth.

  • Novavax Hires Regulatory Expert As Coronavirus Vaccine Inches Closer To Emergency Use Filing

    Novavax, Inc. (NASDAQ: NVAX) is beefing up its executive team as it prepares to release results of its late-stage coronavirus vaccine study and file for emergency use authorization.What Happened: Novavax said it has appointed Dr. Henrietta Ukwu, a fellow of the American College of Physicians, to the newly created role of senior vice president, chief regulatory and quality officer.Ukwu will be responsible for global regulatory strategy and execution as well as quality assurance for its development-stage vaccine candidates, including its COVID-19 vaccine candidate NVX-CoV2373. "Dr. Ukwu brings extensive regulatory affairs and quality expertise and leadership experience at precisely the right time for Novavax, as we advance toward data readouts and regulatory submissions in 2021," Novavax CEO Stanley Erck said in a statement. Related Link: The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off Ukwu most recently served as chief regulatory officer and global head of quality and regulatory at Otsuka Pharmaceuticals, part of Otsuka Holdings Unsponsored ADR Representing Ord Shs (OTC: OTSKY).She has led approval of many products, including Merck & Co., Inc.'s (NYSE: MRK) Varivax, a chickenpox varicella vaccine, and Crixivan, an HIV protease inhibitor that significantly impacted the treatment paradigm of HIV/AIDS.What's Next: Novavax initiated the pivotal Phase 3 study of NVX-CoV2373 in the U.S. and Mexico in late December.The company has an ongoing Phase 3 trial in the U.K. and a Phase 2b study in South Africa. A Phase 1/2 trial is also underway in the U.S. and Australia.The company expects to release data from these trials in the first quarter.NVAX Price Action: Novavax shares were down 0.99% at $128.69 at last check Friday. Related Link: The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges See more from Benzinga * Click here for options trades from Benzinga * Novavax Strikes Another Coronavirus Vaccine Supply Deal: Where Does The Company's Program Stand? * The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GM soars amid electric vehicle push

    GM shares are on a roll this week, hitting an all-time high and gaining an astounding 17% over the past five days alone.

  • Marijuana Stocks Jump On Democratic Senate; Are Any Good Buys Now?

    Marijuana stocks surged as a Democratic Senate adds to cannabis legalization momentum. Are any pot stocks good buys now amid profitability challenges?

  • Plug Power Learns French, and This Analyst Plays La Marseillaise

    For the second time in a week, hydrogen fuel cell company Plug Power (PLUG) had big news to report. Last week, as you may recall, it was a $1.5 billion alliance with Korea's SK Group to build a "hydrogen economy" for South Korea. This week, it's a deal to build fuel cell vans in France alongside local partner Renault -- and although Plug didn't attach a price tag to this one, investors still cheered like mad, sending Plug stock up more than 22% in a day. As Plug revealed Tuesday, it has signed a memorandum of understanding with the French automaker. Through it, the parties expressed interest in forming a 50-50 joint venture within the next six months to supply "turn-key fuel cell vehicle solutions with hydrogen fuel, refueling infrastructures and services" to customers in France -- and capture 30% of the market for fuel cell-powered light commercial vehicles in the country. Renault will provide the automobile manufacturing capability, and Plug will supply the fuel cell systems to make them go "zoom!" Plug will also manufacture hydrogen refueling systems to fuel up the vans on the road. Shareholders weren't the only ones pleased by Plug Power's announcement, and analyst Christopher Souther at B. Riley quickly rushed out a note doubling down on its "buy" rating on Plug stock, and raising his price target more than 50%, to $79 a share. (To watch Souther's track record, click here) Calling Renault a "strong partner" for Plug on the Continent, where the local market for fuel cell-powered light commercial vehicles is expected to grow from essentially zero today, to 500,000 units by 2030. Souther increased his long-range forecast for Plug's commercial vehicles revenues accordingly. In fact, long before 2030, he is valuing Plug stock at 20 times his fiscal 2024 sales forecast. What is that forecast, precisely? Souther didn't say straight out. But a $79 share price would imply an enterprise value of a little over $37 billion for Plug stock, implying that the analyst sees the new relationship with Renault pushing Plug's 2024 revenues up past $1.8 billion -- roughly a six-fold increase over Plug's trailing revenues of $308 million. Curiously, this estimate is nearly twice the $1 billion in fiscal 2024 revenue that Plug itself most recently promised. And here's another curious thing about Souther's predictions: While not expressly putting a number to his 2024 forecast, Souther did give detailed guesses at what Plug will produce nearer term, predicting full-year 2020 sales and full-year 2021 sales as well. In contrast to the average consensus on Wall Street, where most analysts agree Plug did perhaps $329 million in sales last year, Souther thinks the company's revenues were only $291 million. Similarly, consensus estimates for fiscal 2021 put Plug's sales at $444 million -- but Souther sees only $419 million. Now, how the analyst goes from predicting disappointing results for two straight years, to predicting sales twice what Plug itself promises just three years from now is not quite clear. And why he is recommending that investors buy Plug ahead of what, by his own admission, look likely to be sales disappointments is similarly opaque. Then again, as Souther himself laments: No matter how expensive Plug stock gets, "it is tough to fight the secular tailwinds." So, that’s B. Riley's view, what does the Street of the Street have in mind? The current outlook offers a conundrum. On the one hand, based on 10 Buys and 1 Hold, the stock has a Strong Buy consensus rating. However, after soaring so high recently, the analysts expect shares to cool down and anticipate downside of 18% from current levels. (See PLUG stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Biden's Boom: The $30 Trillion ESG Sector Is Set To Explode In 2021

    The ESG mega-trend sent trillions of dollars pouring in last year. But the real boom could be set to take off beginning January 20th